Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retinopathy of prematurity · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes retinopathy of prematurity№ of participants: 277(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.95 [0.78, 1.15]
Studies not reported
Very low
Severe retinopathy of prematurity (stage II or greater)№ of participants: 244(1 RCT) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes severe retinopathy of prematurity (stage II or greater)№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.97 [0.57, 1.65]
Studies not reported
Very low
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Curcuma longa may leads to higher global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Curcuma longa showed no clear difference in adverse events Assessed clinically compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Peppermint/caraway oil probably leads to higher global symptoms of dyspepsia (responders) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Peppermint/caraway oil showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Harmful alcohol use · alcohol use disorder
1 finding from 1 review
Retention [ · alcohol use disorder
Pharmacologic intervention showed no clear difference in retention compared with placebo (low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found